Amethys Insights Private Limited

What Amethys Insights Private Limited does

Amethys Insights Private Limited is a Health Economics and Outcomes Research (HEOR) consulting firm headquartered in Mumbai, India, serving pharmaceutical and biotechnology sponsors across North America, Europe, and Asia-Pacific. Founded in 2021 as SRS HEOR and rebranded to Amethys Insights in 2024, the firm operates from a single delivery center with a small senior-led bench (~13 personnel per firmographic data, 6 listed on its public website). Its service catalog spans Strategic HEOR, Evidence Generation and Synthesis, Advanced Comparative Strategy, Value Communication and Writing, Pharmacovigilance, and Medical Writing — work that underpins HTA submissions, payer access strategy, and reimbursement dossiers for global drug launches. The firm claims more than 25 HTA submissions supported and an 80–90% repeat client rate across geographies including the United States, United Kingdom, Spain, Denmark, the Netherlands, Singapore, and India.

The underlying technology stack is human-expert-driven rather than platform-based: deliverables are produced by senior HEOR consultants using established health-economic modeling frameworks and evidence synthesis methodology (the firm references a "Comparator-First Thinking" approach). The firm holds ISO/IEC 27001:2022 for information security and ISO/IEC 27701:2019 for privacy management — certifications that materially de-risk engagements involving sensitive clinical and patient-level data and are a credentialing requirement for many large pharma procurement teams. Conference positioning at ISPOR EU 2023 (Copenhagen), World EPA Congress 2023 (Amsterdam), and ISPOR 2024 (Barcelona) indicates deliberate channel investment toward senior payer and market access decision-makers.

The business model is project-based professional services: revenue is generated through fee-for-service engagements scoped around specific HEOR, evidence synthesis, value communication, pharmacovigilance, or medical writing deliverables. Customer segments are exclusively enterprise pharmaceutical and biotechnology companies, with no disclosed SMB or long-tail component. The website copyright is held by SRS Life Sciences, indicating a residual corporate relationship with that entity despite the rebrand to Amethys Insights. No funding rounds, acquisitions, or revenue figures are disclosed in the available inputs.

Name

Amethys Insights Private Limited

Legal name

Amethys Insights Private Limited

Website

https://amethysinsights.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

11–50 employees

Short description

Amethys Insights is a Mumbai-based HEOR consultancy serving global pharmaceutical and biotechnology sponsors, delivering strategic HEOR, evidence synthesis, comparative strategy, value communication, pharmacovigilance, and medical writing across the US, Europe, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Healthcare Consulting (HEOR & Pharmacovigilance Services)

NAICS

Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742), Services-Health Services (8000)

akta.pro primary industry

Signal Detection & Safety Analytics (Epidemiology/RWE) (HLAGALAC)

Keywords

• Health economics outcomes research
• Systematic literature review
• HTA submission support
• Pharmacovigilance services
• Medical writing consulting

Headquarters

HQ city

Mumbai

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. HEOR Consulting Services: Project-based consulting engagements for pharmaceutical companies requiring health economics and outcomes research support, including systematic literature reviews, HTA submissions, value dossiers, and pharmacovigilance services.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Amethys Insights is a healthcare consulting firm that delivers Health Economics and Outcomes Research (HEOR), pharmacovigilance, and medical writing services to pharmaceutical and biotechnology clients. Its core Strategic HEOR Service encompasses end-to-end PRISMA-compliant evidence generation (systematic literature reviews, targeted reviews, landscape assessments), advanced comparative analytics (network meta-analysis, indirect treatment comparisons, HTA submission packages), and value communication deliverables (Global Value Dossiers, peer-reviewed manuscripts, abstracts, posters). Dedicated Pharmacovigilance and Medical Writing service lines round out the portfolio.

Product overview

Amethys Insights is a healthcare consulting firm offering an integrated suite of services spanning Health Economics and Outcomes Research (HEOR), Pharmacovigilance, and Medical Writing. The core offering is the Strategic HEOR Service, which comprises three interconnected sub-products: Evidence Generation & Synthesis (SLRs, TLRs, Landscape Assessments), Advanced Comparative Strategy (NMA, HTA Packages), and Value Communication & Writing (GVDs, Scientific Dissemination). These are complemented by dedicated Pharmacovigilance and Medical Writing service lines, providing end-to-end support from clinical development to commercialization.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategic HEOR Service Comprehensive Health Economics and Outcomes Research service for pharmaceutical products across the lifecycle. Encompasses PRISMA-compliant Evidence Generation & Synthesis (systematic literature reviews, targeted and rapid reviews, landscape assessments), Advanced Comparative Strategy (indirect treatment comparisons, network meta-analysis, HTA submission packages), and Value Communication & Writing (Global Value Dossiers, peer-reviewed manuscripts, abstracts, posters). Designed for pharma and biotech teams preparing for HTA submissions to NICE, CADTH, and EU HTA.
• Pharmacovigilance Services Dedicated pharmacovigilance offering supporting pharmaceutical companies in managing the safety profiles of their products. Includes safety data collection, analysis, quality assurance, and regulatory compliance support within ISO/IEC 27001:2022 and ISO/IEC 27701:2019 certified systems. Targeted at pharma and biotech clients needing robust PV operations and compliance support.
• Medical Writing Services Wide range of medical writing services tailored for pharmaceutical and biotechnology companies, covering documentation from early-phase clinical trials through post-market materials. Delivered alongside the Strategic HEOR Service as part of an integrated evidence-to-publication pipeline.

Quantifiable outcome

• Supported 25+ HTA submissions
• +1 more outcomes

Named customers4 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Cytel: Biostatistics and HEOR consultancy with substantial indirect treatment comparison/NMA practice serving pharma evidence generation needs. Overlaps directly with Amethys' Advanced Comparative Strategy and evidence synthesis offerings.
• Genesis Research: Mid-sized HEOR and real-world evidence consultancy serving global pharma with SLRs, NMAs, value dossiers, and HTA submissions. Highly comparable niche positioning and senior-led delivery model.
• Evidera: Multi-modality HEOR and RWE consultancy (PPD/Thermo Fisher) offering value dossiers, SLRs, NMAs, and HTA submission support to pharma/biotech. Directly comparable service mix and buyer set to Amethys' Strategic HEOR Service.
• OPEN Health Group: Global HEOR, market access, and medical communications consultancy serving pharma clients across HTA submissions (NICE, CADTH). Operates comparable senior-led delivery model and is the closest direct competitor in scope, scale aspirations, and buyer (global pharma HEOR teams).
• Mtech Access: UK-based HEOR and market access consultancy focused on HTA submissions (NICE, SMC) for pharma clients. Closely comparable boutique model in size and methodology-led value proposition.
• Precision Medicine Group (Precision HEOR): Specialized evidence-generation and HEOR unit of Precision Medicine Group serving biopharma with value communication, HTA strategy, and SLR/NMA services. Closely comparable in target customer and evidence-services scope.

Broad incumbents

• Xcenda: HEOR and market access division of Cencora (AmerisourceBergen), offering value dossiers, HTA submissions, and market access strategy to pharma manufacturers. Larger, broader portfolio spanning distribution, payer, and evidence services beyond core HEOR.
• Parexel International: Global CRO offering integrated HEOR, market access, and pharmacovigilance within a full clinical development portfolio. Represents the Tier-1 incumbent that smaller HEOR boutiques frequently support or compete against at the enterprise buyer level.
• Covance Market Access (Labcorp Drug Development): Market access and HEOR arm of Labcorp Drug Development, offering value dossiers, payer research, and HTA submissions as part of a broader clinical-commercial services portfolio. Largest-tier incumbent with overlapping buyer relationship.
• IQVIA: Largest global life sciences services firm with substantial HEOR, RWE, and HTA advisory practices alongside commercial technology. Defines the 'premium consultancy' benchmark against which Amethys' cost-effective positioning is sold.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks4 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/amethysindia

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Amethys Insights Private Limited